Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease

Journal of Neural Transmission

Volumn 111, Issue 6, 2004, Pages 725-732

  Shiraishi, M ^a   Kamo, T ^a   Hotta, M ^a   Nemoto, S ^a   Oshima, J ^a   Sugihara, H ^a   Yasaki, S ^a   Kawakami, M ^a   Takahashi, Y ^a   Shimojo, S ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cabergoline; Dopamine agonist; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE;

ADULT; AGED; AKINESIA; ANOREXIA; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; ERGOLINES; HUMANS; PARKINSON DISEASE; PERGOLIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 2642556589     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0110-6     Document Type: Article

References (18)

1. Ahlskog JE, Wright KF, Muenter MD, Adler CH (1996) Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 19: 202-212
2. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329: 1021-1027
3. Calne DB, Burton K, Beckman J, Martin WR (1984) Dopamine agonists in Parkinson's disease. Can J Neurol Sci 11 [Suppl]: 221-224
4. Canesi M, Antonini A, Mariani CB, et al. (1999) An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 106: 925-929
5. Goetz CG, Tanner CM, Glantz RH, Klawans HL (1985) Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 35: 749-751
6. Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL (1989) Agonist substitution in advanced Parkinson's disease. Neurology 39: 1121-1122
7. Goetz CG, Blasucci L, Stebbins GT (1999) Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 52: 1227-1229
8. Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 108: 63-70
9. Hoehn MM, Elton RL (1985) Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 35: 199-206
10. Hutton JT, Koller WC, Ahlskog JE, et al. (1996) Multicenter, placebo-controlled trial of cagbergoline taken once daily in the treatment of Parkinson's disease. Neurology 46: 1062-1065
11. Jori MC, Franceschi M, Giusti MC, et al. (1990) Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Adv Neurol 53: 539-543
12. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG (2000) Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 57: 1461-1463
13. LeWitt PA, Ward CD, Larsen TA, et al. (1983) Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 33: 1009-1014
14. Lieberman A (1992) Long-term experience with selegiline and levodopa in Parkinson's disease. Neurology 42 [Suppl 4]: 32-36
15. Mouradian MM, Chase TN (1994) Improved dopaminergic therapy of Parkinson's disease. In: Marsden CD, Fahn S (eds) Blue books of practical neurology. Movement disorders 3. Butterworth-Heinemann, Oxford, pp 180-190
16. Rinne UK, Bracco F, Chouza C, et al. (1997) Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48: 363-368
17. Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol A, Montastruc JL (1997) Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 63: 584-589
18. Wooten GF (1987) Pharmacokinetics of levodopa. In: Marsden CD, Fahn S (eds) Blue books of practical neurology. Movement disorders 1 and 2. Butterworth-Heinemann, Oxford, pp 231-248